	US 12,331,327 B2
	Carboxyesterase biocatalysts
Kristin K. Brown, Collegeville, PA (US); Brent M. Dorr, Collegeville, PA (US); Douglas E. Fuerst, Collegeville, PA (US); Katherine Joyce Honicker, Collegeville, PA (US); Lydia Sanchez Jordan, Collegeville, PA (US); James Patrick Morrison, Collegeville, PA (US); Nikolay V. Plotnikov, Collegeville, PA (US); Markus Schober, Stevenage (GB); and Rama Voladri, Redwood City, CA (US)
Assigned to GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED, Stevenage (GB)
Filed by GlaxoSmithKline Intellectual Property Development Limited, Middlesex (GB)
Filed on Oct. 13, 2022, as Appl. No. 18/046,295.
Application 18/046,295 is a continuation of application No. 16/771,279, granted, now 11,535,833, previously published as PCT/IB2018/060042, filed on Dec. 13, 2018.
Claims priority of provisional application 62/598,181, filed on Dec. 13, 2017.
Prior Publication US 2023/0193227 A1, Jun. 22, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 9/18 (2006.01); C12P 17/16 (2006.01)

CPC C12N 9/18 (2013.01) [C12P 17/16 (2013.01); C12P 17/165 (2013.01); C12Y 301/01001 (2013.01)]

15 Claims

1. A carboxyesterase polypeptide comprising an amino acid sequence that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 4, wherein the residue corresponding to X198 in SEQ ID NO: 4 is a phenylalanine (F) residue, an isoleucine (I) residue, a tyrosine (Y) residue, a leucine (L) residue, or a methionine (M) residue.